key: cord-0998171-8rvwq2ai
authors: Kroemer, Alexander; Khan, Khalid; Plassmeyer, Matthew; Alpan, Oral; Haseeb, M.A.; Gupta, Raavi; Fishbein, Thomas M.
title: Inflammasome Activation and Pyroptosis in Lymphopenic COVID-19 Liver Patients
date: 2020-07-06
journal: J Hepatol
DOI: 10.1016/j.jhep.2020.06.034
sha: 524a6f85a8c83e8e5efc1bde43b29752dd5243d4
doc_id: 998171
cord_uid: 8rvwq2ai

nan

To the Editor: As has recently been highlighted in the Journal of Hepatology and elsewhere, patients with liver diseases such as non-alcoholic fatty liver disease (NAFLD) or cirrhosis, as well as liver transplant recipients, carry a high risk of morbidity and mortality due to coronavirus disease 2019 (COVID-19) [1] [2] [3] . Many of these patients have additional comorbidities including obesity, diabetes, hypertension, and cardiovascular disease, which are emerging as key predictors of COVID-19 severity [4, 5] . Inflammation and T-cell immune dysregulation are also associated with poor COVID-19 outcomes [6] . To what extent these comorbidities cause immune dysregulation in COVID-19 is unknown; but it is known that they are characterized by chronic inflammation involving activation of the inflammasome [7] , which has been shown to play a key role in antiviral immune responses against other Coronaviruses [8] . We thus hypothesize that heightened inflammasome activity may drive acute on chronic inflammation, leading to immune dysregulation and ultimately severe disease for these comorbid patients when facing COVID-19. In this letter, we share findings that provide preliminary support of this hypothesis based on data from 8 COVID-19 liver patients from the MedStar Georgetown Demographically, the liver patient cohort included patients between the ages of 46 and 70, 5 females and 3 males, and 5 non-white and 3 white patients. Seven patients had liver cirrhosis and 1 had NAFLD. Four had received liver transplantation and 4 were under our care for liver disease. All patients had significant comorbidities that would imply a chronic inflammatory profile. Six patients had severe COVID-19 courses requiring supplemental oxygen and/or ventilator support, and 4 of those patients died, 3 of whom were liver transplant recipients.

Over the course of their COVID-19 hospitalization, all liver patients had elevated levels of transaminases and alkaline phosphatase consistent with previous reports on liver function in COVID-19 patients, high levels of inflammatory markers including CRP, ferritin, and D-dimer, as well as profound lymphopenia (mean length of 7 days and 14 days for the non-lethal and lethal cases, respectively). Specifically, the mean lowest lymphocyte count across the liver cohort was 0.5 K/µL, and for the non-lethal and lethal cases it was 0.7 and 0.3 K/µL, respectively, in line with the controls (overall mean of 0.6, with 0.8 and 0.3 K/µL for non-lethal and lethal, respectively). The mean absolute T-cell count across the liver cohort was low, with 685 /µL, and strikingly lower for lethal cases when compared to non-lethal cases (346 and 1023 /µL, respectively). In the control cohort, the mean absolute T-cell count was 988 /µL with similar levels in the non-lethal and lethal cases. The relatively higher levels in the control cohort lethal cases versus the liver cohort lethal cases could be explained by the fact that 3 of the 4 lethal liver patients were on post-transplant immunosuppression, indicating that immunosuppression could exacerbate COVID-19 induced T-cell lymphopenia. Moreover, overexpression of both CD38+ and HLA-DR+ in CD4+ and 8+ T-cells across the cohorts, with 4 mean values of 8.1% and 26.5% in the liver and 6.2% and 26.7% in the control cohorts, respectively, points to viral-induced T-cell activation.

The T-cell lymphopenia caused us to hypothesize that inflammasome activation might be a driver of pyroptosis-induced T-cell death. This led us to study caspase-1 activation, as its upregulation is the hallmark feature of inflammasome activation. Indeed, we found a global Our patient data corroborate poor COVID-19 outcomes for liver patients, especially for those with inflammatory comorbidities. Furthermore, analysis of lethal cases shows that patients with the lowest T cell counts are more prone to morbid outcomes. The common link between these findings may be the inflammasome, which plays a role in both comorbidities and viral infections. Specifically, our findings suggest that comorbid patients -independent of liver disease -may already have a constitutive chronic activation of the inflammasome, which is further exacerbated by viruses that activate the inflammasome, as has been shown in monocytes and other immune cells in the face of coronaviruses [9] . Strong upregulation of caspase-1 activity in T cells as well as high IL-18 and LDH levels across all patients suggests pyroptosis-mediated programmed cell death occurring downstream of inflammasome activation as a cause of lymphopenia and driver of heightened inflammation in COVID-19 5 similar to SARS-CoV-1 [10] . Pyroptotic T-cell depletion in COVID-19 patients may not only prevent the adaptive immune system from mounting an effective antiviral immune response but also fuel a lethal inflammatory response through release of proinflammatory cytokines such as IL-1beta and IL-18. Our insights about the potentially critical role of the inflammasome in COVID-19 has therapeutic implications beyond liver diseases as it implies upstream prevention of pyroptosis in COVID-19 may be beneficial. 

Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study

High Mortality Rates for SARS-CoV-2 Infection in Patients with Pre-existing Chronic Liver Disease and Cirrhosis: Preliminary Results from an International Registry

Determining risk factors for mortality in liver transplant patients with COVID-19

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Clinical and immunological features of severe and moderate coronavirus disease 2019

Inflammasomes: mechanism of action, role in disease, and therapeutics

NLRP3 Inflammasome-A Key Player in Antiviral Responses

Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Inflammasome

SARS-Coronavirus Open Reading Frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes